ImmunityBio (NASDAQ:IBRX) had its price objective increased by Piper Sandler from $18.00 to $25.00 in a research report released on Wednesday, The Fly reports. The brokerage currently has an overweight rating on the stock.

Shares of NASDAQ:IBRX opened at $18.74 on Wednesday. ImmunityBio has a one year low of $2.83 and a one year high of $45.42.

ImmunityBio Company Profile

ImmunityBio, Inc, an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes.

Further Reading: What is basic economics?

The Fly

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with's FREE daily email newsletter.